Iambic Therapeutics has filed a notice of an exempt offering of securities to raise $124,999,970.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Iambic Therapeutics, Inc. is raising up to $124,999,970.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Iambic Therapeutics, Inc.
Iambics cutting-edge AI-driven platform tackles the most challenging design problems in drug discovery, addressing unmet patient need. Our physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Exploring multiple profiles in parallel ensures that we design molecules to solve the right problems in disease biology. Our AI-driven platform deeply explores chemical space, revealing novel mechanisms of action and delivering diverse high-quality leads. Platform-driven pipeline of first-in-class and best-in-class programs. We are unlocking the untapped potential of known targets and transforming seemingly undruggable targets into opportunities for breakthrough treatments. By placing AI innovations in the hands of our seasoned drug hunters, were optimizing our path towards differentiated therapeutics.
To learn more about Iambic Therapeutics, Inc., visit https://www.iambic.ai/
Iambic Therapeutics, Inc. Linkedin Page: https://www.linkedin.com/company/iambic-ai/
Contact:
Thomas Miller, Chief Executive Officer
626-592-2520
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.